Next-generation basal insulin efsitora demonstrated efficacy and safety  comparable to insulin degludec in patients with type 1 and type 2 diabetes. Published in the Journal of Diabetes Complications, this systematic review and meta-analysis evaluated six RCTs including 2,590 patients, of whom 1,376 received efsitora.

Glycemic outcomes, including HbA1c reduction, fasting glucose, weight change, and achievement of HbA1c <7%, were comparable between groups. Glycemic outcomes, including hemoglobin A1c (HbA1c) reduction, fasting glucose, weight change, and achievement of HbA1c <7%, were comparable between groups.

However, subgroup analyses revealed notable differences: in type 2 diabetes, efsitora was linked to a lower incidence of nocturnal hypoglycemia, while in type 1 diabetes, it was associated with a higher rate of serious adverse events.  These results highlight the importance of tailoring basal insulin choice to patient characteristics.